NCT00002268View on ClinicalTrials.gov

A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
Cytomegalovirus InfectionsHIV Infections
Interventions
DRUG

Sevirumab

Trial Locations (2)

35294

Univ of Alabama at Birmingham, Birmingham

77550

Univ TX Galveston Med Branch, Galveston

Sponsors

Lead Sponsor

Sandoz
All Listed Sponsors
lead

Sandoz

INDUSTRY

NCT00002268 - A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria | Biotech Hunter | Biotech Hunter